EP0573535A1 - Molekularspektroskopieverfahren und -einrichtungen zur gewebediagnose - Google Patents
Molekularspektroskopieverfahren und -einrichtungen zur gewebediagnoseInfo
- Publication number
- EP0573535A1 EP0573535A1 EP92906273A EP92906273A EP0573535A1 EP 0573535 A1 EP0573535 A1 EP 0573535A1 EP 92906273 A EP92906273 A EP 92906273A EP 92906273 A EP92906273 A EP 92906273A EP 0573535 A1 EP0573535 A1 EP 0573535A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- tissue
- spectrum
- light
- radiation
- raman
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 107
- 238000003745 diagnosis Methods 0.000 title claims abstract description 41
- 238000010905 molecular spectroscopy Methods 0.000 title abstract description 4
- 238000001069 Raman spectroscopy Methods 0.000 claims abstract description 81
- 230000005855 radiation Effects 0.000 claims abstract description 37
- 238000001228 spectrum Methods 0.000 claims description 197
- 230000003595 spectral effect Effects 0.000 claims description 33
- 239000000835 fiber Substances 0.000 claims description 28
- 210000001367 artery Anatomy 0.000 claims description 27
- 230000001678 irradiating effect Effects 0.000 claims description 18
- 230000003287 optical effect Effects 0.000 claims description 18
- 238000004611 spectroscopical analysis Methods 0.000 claims description 14
- 230000004044 response Effects 0.000 claims description 10
- 238000002329 infrared spectrum Methods 0.000 claims description 8
- 230000002596 correlated effect Effects 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 3
- 238000010168 coupling process Methods 0.000 claims 3
- 238000005859 coupling reaction Methods 0.000 claims 3
- 238000005102 attenuated total reflection Methods 0.000 abstract description 86
- 238000005259 measurement Methods 0.000 abstract description 17
- 239000000203 mixture Substances 0.000 abstract description 17
- 238000011282 treatment Methods 0.000 abstract description 9
- 230000001575 pathological effect Effects 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 description 163
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 78
- 239000000523 sample Substances 0.000 description 68
- 150000002632 lipids Chemical class 0.000 description 59
- 210000000709 aorta Anatomy 0.000 description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- 235000012000 cholesterol Nutrition 0.000 description 43
- 150000001408 amides Chemical class 0.000 description 38
- 238000005079 FT-Raman Methods 0.000 description 37
- 102000004169 proteins and genes Human genes 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 37
- 235000018102 proteins Nutrition 0.000 description 35
- 238000001237 Raman spectrum Methods 0.000 description 32
- 230000001338 necrotic effect Effects 0.000 description 30
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 29
- 230000005284 excitation Effects 0.000 description 29
- 230000009102 absorption Effects 0.000 description 28
- 238000010521 absorption reaction Methods 0.000 description 28
- 238000005452 bending Methods 0.000 description 21
- 239000013307 optical fiber Substances 0.000 description 21
- 239000000463 material Substances 0.000 description 19
- 230000003143 atherosclerotic effect Effects 0.000 description 18
- 238000005070 sampling Methods 0.000 description 15
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- 208000004434 Calcinosis Diseases 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 11
- 102000016942 Elastin Human genes 0.000 description 11
- 108010014258 Elastin Proteins 0.000 description 11
- 229910019142 PO4 Inorganic materials 0.000 description 11
- 230000002308 calcification Effects 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 229920002549 elastin Polymers 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 11
- 239000010452 phosphate Substances 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- 230000035515 penetration Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000000577 adipose tissue Anatomy 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 238000002095 near-infrared Raman spectroscopy Methods 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 229910000530 Gallium indium arsenide Inorganic materials 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 210000002808 connective tissue Anatomy 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 238000004476 mid-IR spectroscopy Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 150000001841 cholesterols Chemical class 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- SBIBMFFZSBJNJF-UHFFFAOYSA-N selenium;zinc Chemical compound [Se]=[Zn] SBIBMFFZSBJNJF-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 3
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001840 cholesterol esters Chemical class 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 238000011886 postmortem examination Methods 0.000 description 3
- 239000010453 quartz Substances 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 3
- 229940117972 triolein Drugs 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000005253 cladding Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 239000011435 rock Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 125000002328 sterol group Chemical group 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- -1 triglyceride ester Chemical class 0.000 description 2
- 125000005314 unsaturated fatty acid group Chemical group 0.000 description 2
- GTRMJEVFVTWDIU-KPNWGBFJSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol;hydrate Chemical compound O.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 GTRMJEVFVTWDIU-KPNWGBFJSA-N 0.000 description 1
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005068 bladder tissue Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000005350 fused silica glass Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000013152 interventional procedure Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001453 nonthrombogenic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000002352 surface water Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000000411 transmission spectrum Methods 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 238000002460 vibrational spectroscopy Methods 0.000 description 1
- 238000001845 vibrational spectrum Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
- A61B5/0086—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters using infrared radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7253—Details of waveform analysis characterised by using transforms
- A61B5/7257—Details of waveform analysis characterised by using transforms using Fourier transforms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/0233—Special features of optical sensors or probes classified in A61B5/00
- A61B2562/0242—Special features of optical sensors or probes classified in A61B5/00 for varying or adjusting the optical path length in the tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7203—Signal processing specially adapted for physiological signals or for diagnostic purposes for noise prevention, reduction or removal
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
- G01N2021/653—Coherent methods [CARS]
- G01N2021/656—Raman microprobe
Definitions
- Atherosclerotic vessels are at present furnished almost exclusively by angiography, which provides anatomical information regarding plaque size and shape as well the degree of vessel stenosis. The decision of whether an interventional procedure is necessary and the choice of appropriate treatment modality is usually based on this information.
- composition of atherosclerotic plaques vary
- Plaque biopsy is
- optical spectroscopic methods as a means of assessing plague deposits.
- Such "optical biopsies” are nondestructive, as they do not require removal of tissue, and can be performed rapidly with optical fibers and arterial catheters. With these methods, the clinician can obtain, with little additional risk to the patient, information that is necessary to predict which lesions may progress and to select the best treatment for a given lesion.
- optical methods most attention has centered on ultraviolet and/or visible fluorescence. Fluorescence spectroscopy has been utilized to diagnose disease in a number of human tissues, including arterial wall. In arterial wall,
- fluorescence of the tissue has provided for the characterization of normal and atherosclerotic artery.
- the information provided is limited by the broad line width of fluorescence emission signals.
- fluorescence based methods provide information about the electronic structure of the constituent
- Atherosclerosis as well as other diseases which affect the other organs of the body.
- the present invention relates to vibrational spectroscopic methods using Fourier transform infrared (FT-IR) attenuated total reflectance (ATR) and near-infrared (IR) FT-Raman spectroscopy. These methods provide extensive molecular level
- a preferred embodiment utilizes FT-Raman spectra of human artery for distinguishing normal and atherosclerotic tissue.
- Near IR FT-Raman spectroscopy can provide information about the tissue state which is unavailable from fluorescence methods.
- These methods include the steps of irradiating the tissue to be diagnosed with radiation in the infrared range of the electromagnetic spectrum, detecting light emitted by the tissue at the same frequency, or alternatively, within a range of frequencies on one or both sides of the irradiating light, and analyzing the detected light to diagnose its condition.
- Both the Raman and ATR methods are based on the acquisition of information about molecular vibrations which occur in the range of wavelengths between 3 and 300 microns. Note that with respect to the use of Raman shifted light, excitation wavelengths in the ultraviolet, visible and infrared ranges can all produce diagnostically useful information.
- Near IR FT-Raman spectroscopy is ideally suited to the study of human tissue.
- Raman spectroscopy is an important method in the study of biological samples, in general because of the ability of this method to obtain vibrational spectroscopic information from any sample state (gas, liquid or solid) and the weak interference from the water Raman signal in the "fingerprint" spectral region.
- the FT-spectrometer furnishes high throughput and wavelength accuracy which might be needed to obtain signals from tissue and measure small frequency shifts that are taking place.
- Standard quartz optical fibers can be used to excite and collect signals remotely.
- Near IR FT-Raman spectroscopy provides the capability to probe biological substituents many hundred microns below the tissue surface. In particular, for atherosclerotic tissue, calcified deposits below the tissue surface are easily
- the ATR technique offers several features especially suited to sampling of human tissue
- the ATR method can non-destructively probe internal human tissue either by direct contact in a hollow organ (e.g. artery), or by insertion of a needle probe.
- a hollow organ e.g. artery
- a needle probe e.g. a needle probe.
- strong water absorption dominates the spectra of highly hydrated samples such as arterial tissue, obscuring the absorption from other tissue components (see Figure 8).
- Accurate subtraction of the strong water absorption from FT-IR ATR spectra is relatively easy and very reliable with the high dynamic range, linearity, stability, and wavelength precision of available FT spectrometers.
- mid-IR spectra of aqueous protein solutions can be collected with fiber optic ATR probes.
- Such probes are easily adaptable to existing catheters for remote, non-destructive measurements in vivo.
- the mid-IR ATR technique allows clinicians to gather precise histological and biochemical data from a variety of tissues during standard catheterization procedures with minimal additional risk.
- the present methods relate to infrared methods of spectroscopy of various types of tissue and disease including cancerous and pre-cancerous tissue, non-malignant tumors or lesions and
- Another preferred embodiment of the present invention uses two or more diagnostic procedures either simultaneously or sequentially collected to provide for a more complete diagnosis. These methods can include the use of fluorescence of endogenous tissue, Raman shifted measurements and/or ATR measurements.
- Yet another preferred embodiment of the present invention features a single stage spectrograph and charge-coupled device (CCD) detector to collect NIR Raman spectra of the human artery.
- CCD charge-coupled device
- Raman spectra can be collected by the CCD at two slightly different illumination
- Figures 1A-1C are schematic illustrations of preferred systems for providing the spectroscopic measurements of the invention.
- Figure 2 graphically illustrates FT-Raman spectra of human aorta: a) normal artery;
- Figure 3 graphically illustrates FT-Raman spectra of normal human aorta: a) irradiated from intimal side (spectrum multiplied by 3); and b) irradiated from adventitial side (primary adipose tissue). c) NIR FT-Raman spectrum of triglyceride, triolein.
- Figure 4 graphically illustrates FT-Raman spectra from human aorta: a) fibrous plaque; and b) atheromatous plaque, c) FT-Raman spectrum of cholesterol monohydrate powder.
- Figure 5 graphically illustrates FT-Raman spectra of calcified human aorta: a) calcified with fibrous cap; b) excised calcification from a
- Figure 6 graphically illustrates FT-Raman spectra of calcified human aorta: a) calcified plaque with a fibrous cap (spectrum multiplied by 8); and b) exposed calcification.
- Figure 7 graphically illustrates the measured NIR Raman intensity of the 960 cm -1 band (A(960 cm -1 ) indicates the area of this band) in a calcified deposit as a function of depth below the irradiated surface.
- the dashed curve corresponds to the fit of an exponential function to the data with an exponent of 2.94 mm -1 .
- Figure 8 graphically illustrates FT-IR ATR spectra (4000 - 700 cm -1 ) of (a) normal aorta, intimal surface; and (b) buffered saline (0.14M NaCl,pH 7.4).
- Figure 9 graphically illustrates FT-IR ATR spectra (1800 - 800 cm -1 ) after water subtraction: (a) Normal aorta, intimal surface; (b) Sub-adventitial fat; (c) Saline rinsed from the intimal surface of normal aorta.
- Figure 10 graphically illustrates FT-IR ATR spectra (1800 - 800 cm -1 ): (a) Two consecutive water-subtracted spectra of normal aorta, intimal surface, collected immediately after placement on ATR element (solid line) and 10 minutes later (dashed line); (b) Same two spectra as in (a) after lipid subtraction, scaled to have equal maxima.
- Figure 11 graphically illustrates FT-IR ATR spectra (1800 - 800 cm -1 ) , water-and lipid-subtracted: (a) Normal aorta, media layer; (b) Atherosclerotic plaque, intimal surface; (c)
- Atheromatous plaque with intact fibrous cap intimal surface.
- Figure 12 graphically illustrates FT-IR ATR spectra (1800 - 800 cm -1 ) : (a) Necrotic core of atheromatous plaque, water-and lipid-subtracted; (b) Dry film of cholesterol.
- Figure 13 graphically illustrates scatter plot for all samples of the area, A(1050), of the 1050 cm -1 cholesterol band (integrated from 1075 to 1000 cm -1 ) ratioed to the area, A(1550) of the
- FIBROUS includes atherosclerotic and atheromatous plaques with intact fibrous caps
- NECROTIC includes exposed necrotic atheroma cores
- Figure 14 graphically illustrates FT-IR ATR spectra (1800 - 800 cm -1 ): (a) Second derivative spectrum of normal aorta intima ( Figure 8a); (b) Water-subtracted spectrum of same normal aorta intima specimen (same as Figure 9a).
- Figure 15 graphically illustrates a scatter diagram for all the specimens of the area, A(1050) of the 1050 cm -1 cholesterol band plotted versus the area, A(1382), of the 1382 cm -1 cholesterol band. Both cholesterol bands have been normalized to the area, A(1050), of the protein amide II band. All band intensities were calculated from the water-and lipid-subtracted spectra. Tissue categories are the same as in Figure 13. The solid line represents a linear least squares fit to the data.
- Figures 16A and 16B are additional preferred embodiments of ATR probes adapted to make the diagnostic measurements of the present invention.
- Figure 17 is a schematic diagram of the system of Figure 1A modified to use the spectrograph/CCD Raman detector of the present invention.
- Figure 18 is a schematic diagram of a preferred system for implementing the spectrograph/CCD Raman detector of the present invention.
- spectrograph/CCD-Raman spectra of normal human aorta A) Raman plus fluorescence spectrum produced by illuminating the tissue sample with 810 nm laser light; B) Raman difference spectrum produced by subtracting spectra produced by illuminating the tissue sample with 810 and 812 nm laser light; C) resulting Raman spectrum produced by integrating the Raman difference spectrum of B).
- spectrograph/CCD-Raman spectra of an atherosclerotic plaque with a calcified deposit exposed at the surface A) Raman plus fluorescence spectrum produced by illuminating the tissue sample with 810 nm laser light; B) Raman difference spectrum produced by subtracting spectra produced by
- Figure 1A includes separate block diagrams for the system of the invention which utilizes laser light for
- the ablation laser 225, pulse stretcher 229 and the pulse filler/multiplexer 231, 233 produce an output laser ablation pulse of sufficient energy and intensity to remove tissue and sufficient pulse duration to propagate through a fiber optic laser catheter delivery system without damaging the fibers.
- a device 219 is used to contact the tissue such as multiple-fiber laser catheter 10 of Figure 1B with an optical shield.
- the catheter 10 is inserted into the artery and the distal end of the catheter is brought into contact with the lesion.
- a determination is made as to the type of tissue at which each optical fiber 20a-c' is aimed. Only fibers aimed at diseased tissue are activated. Thus, selective tissue removal is obtained.
- this technique is also applicable for guiding surgical procedures in other organs and tissue types such as the colon and bladder.
- the present invention relates to systems and methods of performing spectral diagnostics to diagnose the tissue in front of each fiber.
- a preferred embodiment a laser light source 207 that is coupled to the fibers.
- the diagnostic light is sent to the fiber of choice by the optical fiber selector 217.
- the diagnostic light exits the selected optical fiber and falls on the tissue.
- the tissue absorbs the light and a fraction of the absorbed light is re-emitted, by Rayleigh fluorescence, Raman or other elastic or inelastic light scattering processes.
- This light is returned to the optical fibers and exits from selector 217, and is detected by a photodiode, photomultiplier or other detector 203. Returning light could use different optical fibers than those employed for illumination. Diagnostic subsystem produces the entire spectral signal which is coupled to computer 80.
- the computer stores the information in a memory as a spectrum, which is a graph of light intensity vs. wavelength. This can be displayed immediately on the video display 82 or compared to an existing spectrum stored in the computer and the difference displayed on the spectral display 86. Temporal display 88 can display corrections made for the wavelength dependent sensitivities of the source. Information from either the temporal or spectral display can be stored in the computer 80. The comparative data is shown on numerical display 84 to provide a quantitative measure of the health of the tissue observed.
- a spectral or numerical display which indicates the type of tissue at which the fiber of interest is aimed. If the tissue is plaque, and is to be removed, then fiber selector 217 will align this fiber with the output beam of the high power laser 225. Then, the high power laser 225 is turned on and an appropriate power level is selected for a predetermined amount of time to remove a certain amount of diseased tissue. The beam of laser 225 is transmitted to pulse stretcher 229 and pulse filler/multiplexer 231, 233 to
- the procedure is repeated for different fibers. Where diseased tissue is detected, it is quickly removed.
- the laser catheter 10 nibbles away at the plaque, leaving the healthy artery wall intact.
- the laser catheter 10 will tend to make contact with artery wall 32 at the outside wall of the bend.
- the optical fiber 20c is not fired. The lesion is removed asymmetrically. This allows the laser catheter 10 to follow the lumen 39, 39a around the bend.
- the artery wall 32 is not irradiated and is not perforated. Additional details of this fiber optic catheter 10 are
- the methods can utilize Fourier transform detection to observe the radiation thereby providing improved signal/noise ratios.
- Other techniques e.g. diode array detection and CCD detection
- diode array detection and CCD detection can also be used.
- contributions from major tissue constituents can be "subtracted out” to reveal information about molecules which are present in small concentrations. For example, in ATR water contributions are removed before the "dry" tissue constituents could be studied. Also,
- ATR is "naturally" suited to probe surface disease, such as the superficial cancers of the bladder and GI tract, whereas Raman is well suited to providing information about conditions deep inside tissue (such as breast cancer or stones).
- the ATR tissue sampling depth can be controlled by properly matching the probe surface material to the tissue type.
- the ATR signal is very sensitive to the surface of the waveguide or probe. For example, if the probe surface has an affinity for lipids in the tissue, lipids can migrate to the probe surface, creating a thin lipid layer and producing a large signal. This can be a problem (it can give
- Probes with special surfaces can be developed to prevent this effect or to promote it, in order to search for particular substances in the tissue.
- Raman diagnostic methods permit adjustment of Raman depth by varying the wavelength.
- Raman sampling depth can be controlled to a large extent by probe design.
- Depth information is important if one desires to provide imaging by creating 3D images of small tumors in the brain or breast. Differential techniques based on the ideas of the preceding paragraph might allow accurate localization of such tumors in three dimensions.
- Near-IR Raman can be combined with a sound wave technique (time of flight or standing waves set up in the tissue) ⁇ the sound wave would modulate the Raman signal emanating from a point in the tissue when it passes that point, and the modulated signal could be used to establish the depth of the tissue producing the signal.
- a system employed for the collection of Raman spectral data from excised tissue samples is
- FT-Raman spectra were measured from 0 - 4000cm -1 below the laser excitation frequency with a FT-IR interferometer 40 equipped with a FT-Raman accessory.
- the accessory employed at 180 back scattering geometry and a cooled (77K) InGaAs detector 42.
- a 1064 nm CW Nd:YAG laser 44 can be used for irradiating a sample 46: utilizing 500 mW to 1 W laser power in a 1.0 to 2.5 mm spot 48 at the sample 46 to collect Raman data.
- a pulsed laser source can also be employed.
- sample 46 generated a beam 46 that is directed through plasma filter 48, mirrors 50, 52, focussing lens 54 and mirror or prism 56 before irradiating the sample 46.
- the radiation received by sample 46 undergoes various mechanisms of absorption, reflection and scattering including Raman scattering.
- Some of the light emitted by the tissue is directed toward lens 60 and then through one or more Rayleigh filters 62.
- the collecting lens 60 collects this backscattered light 64 and collimates it.
- the Rayleigh filters 62 removes the elastically scattered light and
- the tissue samples were placed in a suprasil quartz cuvette with a small amount of isotonic saline to keep the tissue moist, with one surface in contact with the irradiated by the laser 44.
- the spectra shown in Figures 2 through 6 were collected with 512 scans at 8 cm -1 resolution (approximately 35 minutes total collection time).
- Human aorta is composed of three distinct layers: intima, media, and adventitia.
- the intima normally less than 300 ⁇ m thick, is the innermost layer and provides a non-thrombogenic surface for blood flow. It is mainly composed of collagen fibers and ground substance.
- the medial layer typically about 500 ⁇ m thick, is quite elastic and serves to smooth the pulsatile blood flow from the heart.
- the structural protein elastin is the major component of aortic media, with some smooth muscle cells present as well.
- the outermost adventitial layer serves as a connective tissue network which loosely anchors the vessel in place, and is mainly made up of lipids, lipoproteins and collagen.
- the intima thickens due to collagen proliferation, fatty necrotic deposits accumulate under and within the collagenous intima, and eventually, calcium builds up, leading to calcium hydroxyapatite deposits in the artery wall.
- Figure 2a shows the FT-Raman spectrum of a full thickness section of aorta grossly identified as normal. Laser irradiation was on the intimal side. The dominant bands appear at 1669 cm -1 and 1452 cm -1 and can be assigned to an amide I backbone and C-H in-plane bending vibration from proteins,
- FIG. 3 Another example of a typical NIR FT Raman spectrum from normal aorta is shown in Figure 3.
- Figure 3a the major vibrational bands observed in normal aorta are all attributable to protein vibrations: the band at 1658 cm -1 is assigned to the amide I
- the spectrum of normal aorta is at least 25% weaker than any of the pathologic samples.
- the peak frequency of the C-H bending band, which averaged for all the normal specimens is 1451+1 cm -1 , is specific to the protein C-H bending mode (See below).
- the weak band near 1335 cm -1 which appears as a shoulder in many of the normal specimens, appears to be specific to elastin, and the weak band at 1004 cm -1 is likely due to phenylalanine residues.
- Figure 3b displays the NIR FT Raman spectrum of the adventitial side of normal aorta.
- the irradiated adventitial surface consisted of several millimeters of visible adipose tissue.
- the bands observed in this adipose material appear to be mainly due to lipid, and in particular triglyceride, with almost no contribution from protein. This is not unexpected, as the triglyceride content of adipose tissue is on the order of 60%.
- This band is distinguished from amide I by its peak frequency and its width, which in this case is 17 cm -1 FWHM.
- Amide I in contrast, is roughly 60 cm -1 wide.
- the dominant C-H bending band is shifted to 1440 cm -1 , characteristic of lipids. This band is about 3 times more intense in adipose tissue than in normal intima, probably a result of the greater number of C-H groups per unit volume in
- the frequencies and structures of the C-H bending and C-C stretching bands suggest that most of the fatty acid chains are in the gauche conformation.
- the FT-Raman spectrum obtained from a diseased artery, an atheromatous plaque, with a thick fibrous connective tissue cap and an underlying necrotic core is shown in Figure 2b.
- the necrotic core of an atheromatous plaque contains cellular debris as well as large accumulations of oxidized lipids and cholesterol.
- the band in the amide I region, peaking at 1665 cm -1 is distinctly narrower in this spectrum compared to normal aorta.
- the in-plane C-H bend, at 1444 cm -1 is relatively more intense and has a distinct shoulder at higher frequency.
- the intense C-H bending band occurs at 1440 cm -1 , characteristic of lipid material. This band is roughly twice as intense as the C-H bending band in normal aorta. The complete absence of a band at 1746 cm -1 indicates that this lipid is not triglyceride. In fact, this lipid appears to be predominantly cholesterols, as identified by the sharp, characteristic band at 700 cm -1 and comparison to the cholesterol spectrum shown in Figure 4c. Again, this is not surprising, since cholesterols accumulate in high concentrations in atherosclerotic lesions. Several of the bands between 1000 and 500 cm -1 are assignable to
- vibrational modes of the sterol rings include the bands at 959, 882, 844, 805, 700, 605, and 546 cm -1 .
- the presence of fatty acid chains in the atheromatous plaque spectra is evidenced by bands at 1300/1262 cm -1 and 1130/1088 cm -1 , due to C-H bending and C-C stretching vibrations, respectively. These bands may contain contributions from cholesterol as well.
- the relative intensities of the fatty acid band at 1300 cm -1 and the sterol ring bands suggest a mixture of free cholesterol and cholesterol-fatty acid esters.
- the relative intensities of the 1130 cm -1 C-C stretching and the 700 cm -1 sterol bands indicate that most of the fatty acid chains are in the gauche conformation, consistent with the predominance of unsaturated fatty acid chains in the cholesterol esters in these plaques. It is
- the NIR FT Raman spectra of some of the fibrous plaques contained two unique bands, at 1519 and 1157 cm -1 . The intensities of these bands are highly correlated, which suggests that they are due to a single component. These bands, which have been previously observed in visibly-excited Raman spectra of atherosclerotic plaques, are assigned to
- the amount of carotenoid in these plaques is probably much smaller than the amounts of cholesterols or proteins, but may be strongly pre- resonance enhanced (14). The carotenoid bands are observed only in this subset of fibrous plaques.
- the NIR FT Raman spectrum of calcified plaque containing a subsurface calcified deposit and an overlying soft fibrous cap, exhibits an intense, sharp, new band at 960 cm -1 ( Figure 6a).
- This band specific to calcified tissue, is assigned to the symmetric stretching vibration of phosphate groups (15), which are present in high concentrations in the solid calcium salts.
- the weaker phosphate antisymmetric stretch is also present at 1072 cm -1 .
- a symmetric stretching vibration of carbonate groups may also contribute to this latter band.
- the phosphate vibrations are easily observed from subsurface deposits in the calcified plaques: the 960 cm -1 band can be observed from deposits up to 1.5 mm beneath a soft tissue cap with the current signal-to-noise level (See below).
- the calcified plaque also displays protein vibrations from the fibrous tissue cap. These include amide I at 1664 cm 1 and amide III near 1257 cm -1 .
- the C-H bending band at 1447 cm -1 suggests a mixture of protein and lipid, and the weak band at 699 cm -1 is likely due to cholesterol that is either in the fibrous cap, the calcified deposit, or both.
- the present methods provide an IR FT-Raman technique for differentiating various stages of atherosclerosis in human aorta. They demonstrate that molecular level information is available using these methods. This information is useful for following the pathogenesis of the disease and in guiding the treatment of different lesions.
- the near IR FT-Raman method with its relatively deep penetration depth, is able to obtain spectroscopic signals from below the tissue surface, yielding details about the atheromatous necrotic tissue and sub-surface calcifications. These signals can be utilized with an optical fiber based imaging system to determine the content and composition of
- hydroxyapatite can be easily detected below the tissue surface, we wished to determine the depth limit of detection using the NIR FT Raman technique.
- NIR FT Raman technique ten 200 ⁇ m sections of aortic media were cut and placed one at a time over a large calcified deposit (6 ⁇ 6 ⁇ 3 mm), and the FT Raman spectra of the 960 cm -1 band monitored as a function of depth below the surface.
- the signal from the calcified deposit was detectable until the deposit was greater than 1.6 mm below the irradiated surface. Even slightly deeper depths could be probed if the focus of the collection optics was moved into the tissue.
- the two dimensional resolution of the NIR FT Raman signal for material below the tissue surface was then tested by placing 1 mm of aortic media above another calcified deposit, and moving the tissue transversely in two dimensions through the laser beam and collection lens.
- the FT Raman signal was observed to drop-off rapidly as the beam and collection optics moved from the calcified deposit.
- the detected FT Raman signal closely followed the geometry of the calcified deposit below the surface, despite the significant scattering of the overlying layer of tissue. This result suggest that the Raman scattered light may be utilized for imaging objects below the tissue surface with minimal image blurring due to elastic scattering in the tissue.
- a second spectroscopic method is also used to obtain molecular vibration information, attenuated total reflective (ATR) of infrared light.
- Human aorta was chosen as an example to
- tissue components including collagen, elastin, and cholesterol to assist in analysis of the spectra.
- the ATR sampling crystal is a rod of high refractive index material which acts as a waveguide for the infrared sampling beam.
- This waveguide can be in the form of a needle that is adapted for penetration into the tissue to be diagnosed.
- the probe will have a geometry suitable for contacting the surface of exposed tissue sites or for contacting internal locations with a catheter.
- FIGs 16A and 16B illustrate preferred embodiments of the invention adapted for ATR diagnostic measurements within the human body.
- a single-ended probe 100 is shown where one or more optical fibers 102 both the incident light to, and the transmitted
- a 100% infrared reflector 106 such as gold is placed at the distal surface 108 of the ATR element 104 functions to return the transmitted light back through the same fiber as well as to provide double pass
- the ATR element 104 can be a separate component optically fastened to the optical fibers 102, or alternatively, it can be constructed from the end of the optical fiber by removing the
- Sampling is provided by placing the ATR element in contact with the tissue 110 of interest. Radiation is transmitted 112 and
- the probe can either be inserted through a standard endoscope or catheter to sample a hollow organ, or, if made with sufficiently thin optical fiber, it can be directly inserted directly into a solid organ as in the case of needle biopsy.
- the distal tip 108 is in the form of a needle.
- configuration on the end of the catheter can be long or shallow.
- a double-ended probe is illustrated in Figure 16B.
- Incident IR beam from FT-IR is transmitted through IR optical fiber 122 to ATR element 128 positioned at the distal end of catheter body 120.
- the ATR element is placed in contact with tissue 126 surface to be sampled. Transmitted light is
- the ATR element may be a
- the specimen to be sampled is placed in optical contact with the surface of the waveguide or ATR element.
- the evanescent wave which extends outside of the waveguide surface is absorbed by the sample in proportion to its absorption coefficient.
- the penetration depth of the evanescent wave into the sample depends on the wavelength of the infrared radiation and the refractive indices of the
- this depth is roughly 1 ⁇ m from 1800 to 700 cm -1 .
- n Z 2 sin 2 ⁇ -n w 2 )1 ⁇ 2 ⁇ /2 ⁇ (n Z 2 sin 2 ⁇ -n w 2 )1 ⁇ 2, where ⁇ is wavelength, ⁇ is angle of incidence and n z and n w are the refractive indices of ZnSe and water respectively.
- Figure 8 shows FT-IR ATR spectra of (a) normal aorta (intimal side) and (b) buffered saline. A comparison of these spectra shows that a majority of the IR absorption of normal intima can be attributed to water, which comprises roughly 80% of the tissue by weight.
- the large, broad bands peaking at 3300 cm -1 and 1636 cm -1 are due to the O-H stretching and H-O-H bending vibrations, respectively, of water, and the weak band at 2120 cm -1 is due to a water combination vibration.
- the 3300 cm -1 and 1636 cm -1 bands also include contributions from the N-H stretching and amide I vibrations.
- the relatively flat absorption between 1500 and 900 cm -1 and the rising absorption below 900 cm -1 is also due
- polypeptide backbone of repeating amide groups is the dominant element.
- repeating hydrocarbon chain is the defining quality. The end result is that these molecular units are present in very large concentrations, and their vibrational bands tend to dominate the spectrum.
- the lipid component observed in the tissue appears to be due to free lipid particles that have equilibrated with the tissue surface water, forming a thin water-lipid film on the tissue surface which is in full optical contact with the
- the ATR element immediately after the tissue specimen is placed upon the crystal.
- the tissue components beneath this film presumably achieve better optical contact with the ATR crystal as the sample settles.
- the content of lipid in a spectrum of aorta intima or media may be influenced by the presence of sub-adventitial fat in the specimen, and the relative lipid-protein absorbencies are accurate to 50% at best with the present experimental design. For the reason, all of the remaining spectra shown are both water and lipid subtracted.
- the major bands in the spectrum may be assigned to protein backbone vibrations. These include the bands at 1648 cm -1 (amide I), 1549 cm -1 (amide II), 1455 cm -1 (C-H bend), 1401 cm -1 (amide C-N stretch), and 1244 cm -1 (amide
- the protein C-H bending band at 1455 cm -1 is distinct from the corresponding vibration in lipid, which occurs as a double-peaked band at 1465/1457 cm -1 .
- FIG. 11a A typical spectrum of the medial layer of normal aorta is shown in Figure 11a. A comparison of this spectrum to that of normal intima ( Figure 10b) fails to reveal any significant differences.
- Atheromatous plaque are shown in Figures 11b and 11c, respectively.
- Figures 11b and 11c For these plaques, only the intact fibrous cap at the intimal surface is probed due to the short penetration depth (1 ⁇ m) of the beam. Any necrotic, atheromatous material beneath this fibrous cap is not sampled. Even so, the fibrous caps of these plaques are known to be compositionally different than normal intima and one might expect these differences to be reflected in the IR ATR spectrum. However, as in the case of media, no consistent differences are observed in the spectra of these plaques ( Figures 11b and 11c) and normal intima ( Figure 10b). This issue will
- Atheromatous core of an atheromatous plaque ( Figure 12a) as compared with the corresponding spectra of normal intima ( Figure 10b) as well as those of intact atherosclerotic ( Figure 11b) and atheromatous ( Figure 11c) plaques.
- the necrotic core was presumably exposed in vivo as disease progressed by ulceration of the overlying intimal fibrous tissue cap.
- the spectrum of necrotic core exposed by dissecting away the fibrous cap of a non-ulcerated atheromatous plaque is similar.
- a new band appears at 1050 cm -1 , with a secondary peak at 1023 cm -1 .
- necrotic core spectrum exhibits an increase and frequency shift in the 1466 cm -1 band as compared with the 1455 cm -1 protein band in normal intima as well as a set of unique bands near 1382 cm -1 .
- These characteristic bands are found in the spectra of all the exposed necrotic core samples and in none of the other samples (see below). The source of these unique bands in the
- necrotic core spectra may be cholesterol, which is known to accumulate in large amounts in atheromatous cores.
- An ATR spectrum of cholesterol (dry film) is shown in Figure 12b.
- the three major bands unique to the necrotic core, near 1463 cm -1 , 1382 cm -1 , and 1050 cm -1 match closely in position and relative intensities with the three main cholesterol bands at 1466 cm -1 , 1377 cm -1 , and 1056 cm -1 .
- Each of the main cholesterol bands has a secondary peak, which also appear to be present in the necrotic core bands.
- Atherosclerosis by mid-IR spectroscopy have been limited to date. It has been reported that ATR spectra have been recorded from partially dried human artery, among other tissues. In comparing a normal aorta from an infant to an atherosclerotic plaque in an adult, they observed increases in several bands in the atherosclerotic aorta. Most of these bands were associated with lipids and
- IR spectroscopy has been employed to determine the chemical composition of calcified atherosclerotic deposits.
- a more detailed IR study of atherosclerotic aorta involves recorded IR transmission spectra from thin layers sectioned at different depths into the arterial wall. Results showed increased absorption near 1739 cm -1 in the fatty (atheromatous) regions of plaque, which was attributed to absorption by cholesterol esters in the plaque. IR spectra from the fibrous tissue cap at the surface of the plaques were similar to normal intima.
- spectra collected with the ATR method are not equivalent to IR absorption spectra, but depend on properties of the ATR material and the sample in addition to the sample absorption coefficient. For instance, the penetration depth of the evanescent sampling wave depends on the refractive indices of the ATR material and the sample. However, the refractive indices of both ZnSe and human tissue are expected to vary slowly with frequency between 1800 and 700 cm -1 and such variations will at most affect the relative intensities of bands at different frequencies. All of the structure observed in the tissue spectra is attributed to absorption bands in the tissue.
- the component absorptions observed in an ATR spectrum also depends upon the optical contact of the sample and ATR element.
- the small penetration depth of the evanescent wave into the tissue sample implies that only a 5 ⁇ m thick layer, and preferably about 1 micron, of material at the surface is observed. This is referred to as the near surface region of the tissue for the purposes of this application.
- the tissue deeper than 5 microns from the surface is defined as the sub-surface region.
- This thin, sampled near-surface layer may differ in composition with the bulk sample. For example, a film of free water may be present on the surface of wet tissue, with different levels of some molecular species of the tissue relative to their
- the varied affinities for the ATR material of different moieties in the tissue may play an important role in the intensities of the observed bands.
- plaque fibrous cap intima and normal intima ATR spectra.
- ATR elements made of other substances with different biochemical affinities the spectral differences among these tissues can be substantially enhanced depending on the tissue type.
- the spectral lineshape of water varies rather slowly with frequency over much of the region of interest, especially between 1500 and 700 cm -1 . Therefore, any method which filters this slower variation and spares the sharper features of the non-water bands can separate the water and non-water components.
- the amide II band in normal intima ( Figure 14b) has a very weak shoulder near 1518 cm -1 , and the C-H bending region near 1468 cm -1 appears to include two overlapping peaks.
- the 1518 cm -1 band is clearly visible, and the C-H region exhibits two separate peaks at 1469 and 1456 cm -1 .
- the second derivative spectrum allows a more precise
- composition of tissue as determined from an ATR spectrum may not be precisely identical to the composition of the bulk tissue.
- the tissue composition can also be determined from overlapping bands by first deconvolving the bands of interest into their individual components. This is especially easy if one component has an additional, isolated band elsewhere in the spectrum.
- An example is the 1465 cm -1 C-H bending region, which is due to different tissue components with distinct spectral features in this region.
- this band is attributed to a combination of lipid and protein components. Since the lipid component also exhibits the isolated 1744 cm -1 band, this band can be used to subtract the lipid C-H bending component and isolate the protein C-H bending component at 1455 cm -1 ( Figure 10b), effectively deconvolving this band. Note that this deconvolution depends on having a reliable spectrum of one of the individual components, which, in this example, is the lipid spectrum in Figure 9b.
- the baseline-subtracted area of the 1050 cm -1 band, A(1050), is plotted versus that of the 1382 cm -1 band, A(1382), for all the samples,
- the present systems and methods demonstrate that infrared spectra of moist, bulk tissues can be reliably obtained with the ATR technique. Although water is the dominant absorber throughout much of the mid-infrared region, the high quality spectra acquired with the FT-IR ATR technique allow for accurate subtraction of the water signal.
- composition of arterial tissue non-destructively There methods are also applicable to the study and diagnosis of other tissues and tissue conditions, such as neoplasia.
- NIR Raman spectroscopy using a single stage spectrograph and a charge coupled device (CCD) detector offers superior sensitivity over the Nd:YAG excited FT-Raman system of Figures 1A and 1C.
- CCD charge coupled device
- a CCD can be used to detect the Raman scattered signals while still avoiding fluorescence excitation in most molecules.
- the system can operate usefully in the range of 750 nm to 1050 nm. Although the fluorescence emission from tissue is significantly higher with 810 nm than with 1064 nm excitation, the Raman signals are readily observed.
- the dominant noise source in the spectrograph/CCD system is shot noise associated with the fluorescence emission, which is 2-3 orders of magnitude smaller than the dark current noise of the InGaAs detector, which is the dominant noise source in the FT-Raman system.
- Figure 17 shows the laser diagnosis
- the diagnostic subsystem 201' includes a single stage spectrograph 310 and charge-coupled device (CCD) detector 312 for collecting near-infrared (NIR) Raman spectra from intact human arterial tissue.
- CCD charge-coupled device
- the fluorescence emission from human artery tissue is sufficiently weak to observe Raman bands more rapidly with the spectrograph/CCD system than with the 1064 nm excited FT-Raman system of Figures 1A and 1C.
- NIR Raman spectral data from excised tissue samples using a spectrograph and a charge coupled device (CCD) array is illustrated in Figure 18.
- NIR Raman spectra were measured from 100 - 2000 cm -1 below the laser excitation frequency with a single stage imaging spectrograph 310 (Acton Model ARC275, 0.25 m, F/3.8) and a CCD array 312
- System 300 can use a NIR 810 nm Nd:YAG pumped pulsed dye laser 314 operating at 10 Hz for
- a CW or diode laser source can also be employed.
- Laser 314 generated a laser beam 316 which is directed by mirror 318 through focusing optics 320 to impinge on sample 46 mounted behind a transparent window 321.
- the laser beam was focused on the sample at a 70° angle of incidence, yielding a spot size of 0.7 ⁇ 2 mm on the tissue surface.
- the average incident power at the sample was maintained at 20 mW to avoid excessive peak intensities during an individual pulse.
- the spectral signals were observed to be linear over a range of average incident powers from 2 to 20 mW.
- a portion of the scattered light 322 emitted by sample 46 was collected by collecting optics 324 at a 90° angle relative to the incident laser beam.
- Collecting optics 324 collimates and F/matches the collected light for the spectrograph 310.
- the collected light Prior to entering the entrance slit of the spectrograph 310, the collected light was passed through a series of Schott glass filters 326 which attenuated the elastically scattered component of the collected light.
- the combined effect of the Schott glass filters provided an optical density of 7 at 810 nm, a transmission of 20% at 850 nm (580 cm -1 from 810 nm), and a transmission of 85% above 900 nm (1200 cm -1 ).
- the spectrograph 310 utilized a 200 ⁇ m slit width and a 600 groove/mm grating blazed at 1 ⁇ m and could be scanned to provide spectral coverage over different wavelength regions.
- the 200 ⁇ m slit width provided a resolution of roughly 15 cm -1 .
- the CCD array 312 consisted of 298 (column) by 1152 (row) pixel elements having a total active area of 6.7 mm ⁇ 26 mm, with the short axis parallel to the slit.
- the CCD array was cooled to -110°C to eliminate dark current.
- Each row of pixels was binned to reduce readout noise.
- Commercially available CCD detectors offer extremely low detector noise and usable quantum efficiencies out to 1050 nm and provide substantial advantages over InGaAs and other NIR detectors. These advantages outweigh the lower throughput of the grating spectrograph, provided that broadband fluorescence interference is not too great with the shorter excitation
- Excised human aorta samples 46 obtained at the time of post-mortem examination were rinsed with isotonic saline solution (buffered at pH 7.4), snap-frozen in liquid nitrogen, and stored at -85°C.
- Atherosclerotic areas of tissue were identified by gross inspection, separated, and sliced into roughly 8 ⁇ 8 mm pieces.
- the tissue samples 46 were placed in a suprasil quartz cuvette with a small amount of isotonic saline to keep the specimens moist, and with one surface in contact with the transparent window 321 and irradiated by the laser 314.
- Raman spectra were typically measured between 100 cm -1 and 2000 cm -1 below the laser excitation frequency. Each spectrum was background subtracted to remove the DC offset of the A/D converter of the CCD controller. In addition, hot pixels due to high energy radiation events were removed from the recorded spectrum by applying a median filter having a 7 pixel wide window as to each spectrum. Raman frequencies were calibrated with the spectra of benzene and barium sulfate powder and are accurate to ⁇ 5 cm -1 . The spectra were not corrected for the wavelength dependent response of the filters, spectrograph, and CCD. For each spectrum shown in the following Figures, Raman signals were
- Figure 19A shows the Raman spectra of a normal aorta sample excited with 810 nm laser light and collected with the spectrograph/CCD system 300.
- the broadband background emission which is presumably due to tissue fluorescence, is roughly five times more intense than the strongest Raman bands at 1650, 1451, 1330, and 1253 cm -1 .
- the shot noise associated with detecting this background emission is substantially smaller than the Raman signals, allowing the Raman bands to be made distinct after the background emission signals are removed through filtering or subtraction.
- the shot noise is typically random noise exhibiting a Poisson distribution and is associated with the detector and/or the background emission itself.
- the fluorescence background emission from the arterial pathology tissue types described is 3 to 4 orders of magnitude larger than the Raman signals, and the shot noise associated with this stronger background emission completely obscures the Raman bands even after the background emissions are removed.
- the signal-to-noise ratio of the spectrum of normal aorta collected with the spectrograph/CCD system 300 with 20 mW incident power and 5 minutes collection time (Figure 19A) is similar to that obtained with the FT-Raman system of Figure 1C with 500 mW incident power and 35 minute collection time. Since the observed spectral signal-to-noise ratios are similar, we estimate that the noise level observed with the CCD detector 312 of Figure 18 is roughly 3400 times less than that observed with the InGaAs detector 42 of Figure 1C.
- the major noise source is the shot noise of the dark current
- the dominant noise source is the shot noise of the broadband tissue emission, as the dark current and readout electrons of the CCD are much smaller than this emission.
- the FT-Raman and spectrograph/CCD systems can be compared as follows.
- the incident intensity is 640 mW/mm 2 .
- the quantum efficiency of the InGaAs detector at 1200 nm is 0.7, and the FT-spectrometer throughput is 1.1 mm 2 sr, and the transmission efficiency of the FT-spectrometer and filters is roughly 0.062.
- the incident intensity is 14 mW/mm 2 .
- the CCD quantum efficiency is 0.15 at 900 nm
- the spectrograph throughput is 0.043 mm 2 sr
- the transmission efficiency of the spectrograph and filters is 0.24. Combining these factors and taking into account the v 4 dependence of the Raman cross-sections, the signal level measured by the FT-Raman spectrum is estimated to be 3400 times greater than that of the spectrograph/CCD spectrum.
- the collection time could be reduced by a factor of 40, to 8 seconds, with no change in the spectral signal-to-noise ratio.
- the noise level can be further reduced by using longer excitation wavelengths which minimize the tissue fluorescence emission.
- the optimum excitation wavelength also depends on the fluorescence excitation profile of the tissue. For tissue types that exhibit little fluorescence emission at visible wavelengths, such as colon and bladder tissue, the CCD can be operated at visible or near visible wavelengths to take advantage of increased quantum efficiency of the CCD at these wavelengths.
- the throughput of a 500 ⁇ m core, 0.2 numerical aperture fused silica optical fiber is 0.03 mm 2 sr, which is roughly the same as that of the spectrograph/CCD system. This means that the present lens collection system can be replaced with an optical fiber probe, as is required for in vivo operation, with no additional loss in signal.
- Figure 19A shows that although the shot noise due to the broadband tissue emission is relatively small, the sloping broadband fluorescence emission still obscures the sharper Raman signals and
- Figure 19B This operation is mathematically analogous to taking the derivative of the Raman spectrum, so that the original Raman spectrum can be recovered by integrating the difference spectrum, as shown in Figure 19C.
- the fluorescence background is greatly reduced in Figure 19C as compared with
- Some weaker bands may also be identified, such as the phosphate/carbonate band at 1070 cm -1 , although these are obscured by the large fluorescence
- the Raman spectrum of adventitial adipose tissue is shown in Figure 21, which can be compared to the FT-Raman spectrum shown in Figure 5c.
- the broadband emission is similar to that of normal aorta, while the Raman bands, due mainly to triglycerides in the tissue, are very strong, resulting in an excellent spectral signal-to-noise ratio.
- the spectrograph/CCD system with 810 nm excitation offers a faster alternative to FT-Raman with 1064 nm excitation and which has greater sensitivity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Artificial Intelligence (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Mathematical Physics (AREA)
- Chemical & Material Sciences (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Signal Processing (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66107791A | 1991-02-26 | 1991-02-26 | |
US661077 | 1991-02-26 | ||
PCT/US1992/000420 WO1992015008A1 (en) | 1991-02-26 | 1992-01-17 | Systems and methods of molecular spectroscopy to provide for the diagnosis of tissue |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0573535A1 true EP0573535A1 (de) | 1993-12-15 |
EP0573535B1 EP0573535B1 (de) | 2000-12-27 |
Family
ID=24652118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92906273A Expired - Lifetime EP0573535B1 (de) | 1991-02-26 | 1992-01-17 | Molekularspektroskopieverfahren und -einrichtungen zur gewebediagnose |
Country Status (7)
Country | Link |
---|---|
US (3) | US6690966B1 (de) |
EP (1) | EP0573535B1 (de) |
JP (1) | JPH06505183A (de) |
AT (1) | ATE198375T1 (de) |
CA (1) | CA2104960C (de) |
DE (1) | DE69231614T2 (de) |
WO (1) | WO1992015008A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3607875A1 (de) * | 2018-08-10 | 2020-02-12 | Samsung Electronics Co., Ltd. | Bestimmung einer analytkonzentration mittels raman-spektroskopie |
Families Citing this family (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06505183A (ja) * | 1991-02-26 | 1994-06-16 | マサチユセツツ・インスチチユート・オブ・テクノロジー | 組織を診断するための分子分光計のシステムおよび方法 |
US5539207A (en) * | 1994-07-19 | 1996-07-23 | National Research Council Of Canada | Method of identifying tissue |
US5697373A (en) * | 1995-03-14 | 1997-12-16 | Board Of Regents, The University Of Texas System | Optical method and apparatus for the diagnosis of cervical precancers using raman and fluorescence spectroscopies |
US5991653A (en) * | 1995-03-14 | 1999-11-23 | Board Of Regents, The University Of Texas System | Near-infrared raman spectroscopy for in vitro and in vivo detection of cervical precancers |
US5615673A (en) * | 1995-03-27 | 1997-04-01 | Massachusetts Institute Of Technology | Apparatus and methods of raman spectroscopy for analysis of blood gases and analytes |
US5733739A (en) * | 1995-06-07 | 1998-03-31 | Inphocyte, Inc. | System and method for diagnosis of disease by infrared analysis of human tissues and cells |
US5873831A (en) * | 1997-03-13 | 1999-02-23 | The University Of Utah Technology Transfer Office | Method and system for measurement of macular carotenoid levels |
US20010048077A1 (en) * | 1997-10-27 | 2001-12-06 | Afanassieva Natalia I. | Apparatus and method for spectroscopic analysis of human or animal tissue or body fluids |
WO1999022640A2 (en) * | 1997-10-30 | 1999-05-14 | Hypermed Imaging, Inc. | Multispectral/hyperspectral medical instrument |
US6937885B1 (en) | 1997-10-30 | 2005-08-30 | Hypermed, Inc. | Multispectral/hyperspectral medical instrument |
AU1401599A (en) * | 1997-11-12 | 1999-05-31 | Lightouch Medical, Inc. | Method for non-invasive measurement of an analyte |
DE69938493T2 (de) | 1998-01-26 | 2009-05-20 | Massachusetts Institute Of Technology, Cambridge | Endoskop zur erfassung von fluoreszenzbilder |
US6364829B1 (en) | 1999-01-26 | 2002-04-02 | Newton Laboratories, Inc. | Autofluorescence imaging system for endoscopy |
US6721582B2 (en) | 1999-04-06 | 2004-04-13 | Argose, Inc. | Non-invasive tissue glucose level monitoring |
US6728560B2 (en) | 1998-04-06 | 2004-04-27 | The General Hospital Corporation | Non-invasive tissue glucose level monitoring |
US7899518B2 (en) | 1998-04-06 | 2011-03-01 | Masimo Laboratories, Inc. | Non-invasive tissue glucose level monitoring |
US6505059B1 (en) | 1998-04-06 | 2003-01-07 | The General Hospital Corporation | Non-invasive tissue glucose level monitoring |
US7433035B2 (en) * | 1998-06-29 | 2008-10-07 | San Diego State University Research Foundation | Detection of carbon halogen bonds |
US6289230B1 (en) | 1998-07-07 | 2001-09-11 | Lightouch Medical, Inc. | Tissue modulation process for quantitative noninvasive in vivo spectroscopic analysis of tissues |
DE19836496A1 (de) * | 1998-08-12 | 2000-02-17 | Karsten Hoeland | Faseroptische Messung der Myokardkontraktion |
US8024027B2 (en) | 1998-09-03 | 2011-09-20 | Hyperspectral Imaging, Inc. | Infrared endoscopic balloon probes |
US6741884B1 (en) | 1998-09-03 | 2004-05-25 | Hypermed, Inc. | Infrared endoscopic balloon probes |
US6503478B2 (en) | 1999-01-13 | 2003-01-07 | Lightouch Medical, Inc. | Chemically specific imaging of tissue |
NZ529432A (en) | 1999-01-26 | 2005-07-29 | Newton Lab Inc | Autofluorescence imaging system for endoscopy |
US6205354B1 (en) | 1999-06-18 | 2001-03-20 | University Of Utah | Method and apparatus for noninvasive measurement of carotenoids and related chemical substances in biological tissue |
US6734962B2 (en) | 2000-10-13 | 2004-05-11 | Chemimage Corporation | Near infrared chemical imaging microscope |
US7328058B2 (en) * | 2000-01-04 | 2008-02-05 | Gamma Medica-Ideas, Inc. | Intravascular imaging detector |
JP2003522578A (ja) | 2000-02-18 | 2003-07-29 | アーゴス インク | 不均質組織における空間的に平均された励起−発光マップの生成 |
WO2001078587A2 (en) * | 2000-04-13 | 2001-10-25 | National Research Council Of Canada Ltd. | Tissue viability/health monitor utilizing near infrared spectroscopy |
DE10027100C2 (de) | 2000-05-31 | 2002-08-08 | Klaus Mueller-Dethlefs | Verfahren und Vorrichtung zum Nachweisen von Substanzen in Körperflüssigkeiten |
US7050842B2 (en) * | 2000-07-11 | 2006-05-23 | Lightouch Medical, Inc. | Method of tissue modulation for noninvasive measurement of an analyte |
EP1301118B1 (de) | 2000-07-14 | 2006-09-06 | Xillix Technologies Corp. | Kompaktes fluorezenz endoskopisches video system |
US6841388B2 (en) * | 2000-12-05 | 2005-01-11 | Vysis, Inc. | Method and system for diagnosing pathology in biological samples by detection of infrared spectral markers |
US7039452B2 (en) | 2002-12-19 | 2006-05-02 | The University Of Utah Research Foundation | Method and apparatus for Raman imaging of macular pigments |
US20060241496A1 (en) | 2002-01-15 | 2006-10-26 | Xillix Technologies Corp. | Filter for use with imaging endoscopes |
US7647092B2 (en) | 2002-04-05 | 2010-01-12 | Massachusetts Institute Of Technology | Systems and methods for spectroscopy of biological tissue |
US20040068193A1 (en) * | 2002-08-02 | 2004-04-08 | Barnes Russell H. | Optical devices for medical diagnostics |
US7689268B2 (en) | 2002-08-05 | 2010-03-30 | Infraredx, Inc. | Spectroscopic unwanted signal filters for discrimination of vulnerable plaque and method therefor |
US7376456B2 (en) * | 2002-08-05 | 2008-05-20 | Infraredx, Inc. | Near-infrared spectroscopic analysis of blood vessel walls |
CA2404891C (en) * | 2002-10-25 | 2003-11-18 | Nir Technologies Inc. | Method of in-vivo measurement of fat content of a body and apparatus therefor |
DE10304221A1 (de) * | 2003-01-30 | 2004-08-12 | Carl Zeiss | Vorrichtung zum Behandeln von Körpergewebe |
US20040254479A1 (en) | 2003-02-20 | 2004-12-16 | John Fralick | Bio-photonic feedback control software and database |
US7486978B2 (en) * | 2003-04-24 | 2009-02-03 | Koninklijke Philips Electronics N.V. | Catheter head |
US7181219B2 (en) | 2003-05-22 | 2007-02-20 | Lucent Technologies Inc. | Wireless handover using anchor termination |
US20050119587A1 (en) * | 2003-07-01 | 2005-06-02 | University Of Michigan | Method and apparatus for evaluating connective tissue conditions |
WO2005004714A1 (en) * | 2003-07-01 | 2005-01-20 | The Regents Of The University Of Michigan | Method and apparatus for diagnosing bone tissue conditions |
CA2535843A1 (en) * | 2003-08-19 | 2005-06-23 | Cornell Research Foundation, Inc. | Optical fiber delivery and collection system for biological applications such as multiphoton microscopy, spectroscopy, and endoscopy |
US7803624B2 (en) | 2003-09-30 | 2010-09-28 | Cytyc Corporation | Automated cytological sample classification |
US8571640B2 (en) * | 2003-12-11 | 2013-10-29 | The Regents Of The University Of California | Catheter based mid-infrared reflectance and reflectance generated absorption spectroscopy |
JP2010286493A (ja) * | 2004-01-23 | 2010-12-24 | Horiba Ltd | 基板検査装置 |
US20050278184A1 (en) * | 2004-06-10 | 2005-12-15 | John Fralick | Bio-photonic feedback control software and database |
US20060281068A1 (en) * | 2005-06-09 | 2006-12-14 | Chemimage Corp. | Cytological methods for detecting a disease condition such as malignancy by Raman spectroscopic imaging |
US7697576B2 (en) | 2004-05-05 | 2010-04-13 | Chem Image Corporation | Cytological analysis by raman spectroscopic imaging |
US20050250091A1 (en) * | 2004-05-05 | 2005-11-10 | Chemlmage Corporation | Raman molecular imaging for detection of bladder cancer |
US7046359B2 (en) * | 2004-06-30 | 2006-05-16 | Chemimage Corporation | System and method for dynamic chemical imaging |
US7580126B2 (en) * | 2004-06-30 | 2009-08-25 | Chemimage Corp. | Method and apparatus for producing a streaming Raman image of nucleation, aggregation, and chemical interaction |
US20060098194A1 (en) * | 2004-11-08 | 2006-05-11 | David Tuschel | Method and apparatus for determining change in an attribute of a sample during nucleation, aggregation, or chemical interaction |
US7394542B2 (en) | 2004-08-18 | 2008-07-01 | Chemimage Corporation | Method and apparatus for chemical imaging in a microfluidic circuit |
US7218822B2 (en) * | 2004-09-03 | 2007-05-15 | Chemimage Corporation | Method and apparatus for fiberscope |
US20060111622A1 (en) * | 2004-10-07 | 2006-05-25 | Sean Merritt | Apparatus and method for monitoring deep tissue temperature using broadband diffuse optical spectroscopy |
KR100700913B1 (ko) * | 2004-10-20 | 2007-03-28 | 고려대학교 산학협력단 | 공초점 라만 분광법을 이용한 조직으로부터의 자기-형광신호 감소 방법 |
US7365839B2 (en) | 2004-11-03 | 2008-04-29 | Nu Skin International, Inc. | Process and compositions for synthetic calibration of bio-photonic scanners |
US7417740B2 (en) * | 2004-11-12 | 2008-08-26 | Medeikon Corporation | Single trace multi-channel low coherence interferometric sensor |
GB0426993D0 (en) | 2004-12-09 | 2005-01-12 | Council Cent Lab Res Councils | Apparatus for depth-selective raman spectroscopy |
US7840254B2 (en) * | 2005-01-18 | 2010-11-23 | Philips Electronics Ltd | Electromagnetically tracked K-wire device |
US7688440B2 (en) | 2005-01-27 | 2010-03-30 | Prescient Medical, Inc. | Raman spectroscopic test strip systems |
US7651851B2 (en) * | 2005-01-27 | 2010-01-26 | Prescient Medical, Inc. | Handheld Raman body fluid analyzer |
US7524671B2 (en) * | 2005-01-27 | 2009-04-28 | Prescient Medical, Inc. | Handheld raman blood analyzer |
US20060170916A1 (en) * | 2005-01-31 | 2006-08-03 | Voigt Thomas C | Method and apparatus for variable-field illumination |
US7283241B2 (en) * | 2005-01-31 | 2007-10-16 | Chemimage Corp. | Method and apparatus for a microscope image selector |
US7060955B1 (en) * | 2005-01-31 | 2006-06-13 | Chemimage Corporation | Apparatus and method for defining illumination parameters of a sample |
EP1844314A4 (de) * | 2005-01-31 | 2009-09-23 | Chemimage Corp | Vorrichtung und verfahrenzur chemischen abbildung einer biologischen probe |
DE202005003411U1 (de) * | 2005-02-24 | 2006-07-06 | Karl Storz Gmbh & Co. Kg | Multifunktionales Fluoreszenzdiagnosesystem |
US20060221335A1 (en) * | 2005-04-04 | 2006-10-05 | Bangalore Arjun S | Method and apparatus for interactive hyperspectral image subtraction |
US7956991B2 (en) | 2005-04-04 | 2011-06-07 | Chemimage Corporation | Method and apparatus for interactive hyperspectral image subtraction |
JP5001934B2 (ja) * | 2005-04-15 | 2012-08-15 | バイエル・ヘルスケア・エルエルシー | 体内グルコースを測定する非侵襲的システム及び方法 |
US7725169B2 (en) * | 2005-04-15 | 2010-05-25 | The Board Of Trustees Of The University Of Illinois | Contrast enhanced spectroscopic optical coherence tomography |
WO2006116637A2 (en) * | 2005-04-27 | 2006-11-02 | Massachusetts Institute Of Technology | Raman spectroscopy for non-invasive glucose measurements |
WO2006127766A1 (en) * | 2005-05-25 | 2006-11-30 | Bayer Healthcare Llc | Methods of using raman spectral information in determining analyte concentrations |
US20070038123A1 (en) * | 2005-06-02 | 2007-02-15 | Newton Laboratories, Inc. | Optical probe for Raman scattering from arterial tissue |
US7330747B2 (en) * | 2005-06-07 | 2008-02-12 | Chemimage Corporation | Invasive chemometry |
US7330746B2 (en) * | 2005-06-07 | 2008-02-12 | Chem Image Corporation | Non-invasive biochemical analysis |
US8253936B2 (en) * | 2008-08-08 | 2012-08-28 | Chemimage Corporation | Raman characterization of transplant tissue |
DE102005028268B4 (de) * | 2005-06-14 | 2013-12-12 | Forschungsverbund Berlin E.V. | Verfahren und Vorrichtung zur Erzeugung und Detektion eines Raman-Spektrums |
US7655003B2 (en) | 2005-06-22 | 2010-02-02 | Smith & Nephew, Inc. | Electrosurgical power control |
US7411188B2 (en) * | 2005-07-11 | 2008-08-12 | Revera Incorporated | Method and system for non-destructive distribution profiling of an element in a film |
US9103793B2 (en) * | 2005-07-22 | 2015-08-11 | Massachusetts Institute Of Technology | Intrinsic Raman spectroscopy |
US20070027362A1 (en) * | 2005-07-27 | 2007-02-01 | Olympus Medical Systems Corp. | Infrared observation system |
US7729749B2 (en) * | 2005-09-01 | 2010-06-01 | The Regents Of The University Of Michigan | Method and apparatus for evaluating connective tissue conditions |
GB0606891D0 (en) | 2006-04-05 | 2006-05-17 | Council Cent Lab Res Councils | Raman Analysis Of Pharmaceutical Tablets |
AT502855B1 (de) * | 2005-11-30 | 2009-10-15 | Oridis Biomed Forschungs Und E | Verfahren und vorrichtung zur automatischen zerstörungsfreien analyse einer vielzahl von biologischen proben |
US7233870B1 (en) * | 2006-01-13 | 2007-06-19 | Thermo Electron Scientific Instruments Llc | Spectrometric data cleansing |
WO2007084933A2 (en) * | 2006-01-20 | 2007-07-26 | The General Hospital Corporation | Systems and processes for providing endogenous molecular imaging with mid-infared light |
WO2007090147A2 (en) * | 2006-01-31 | 2007-08-09 | The Board Of Trustees Of The University Of Illinois | Method and apparatus for measurement of optical properties in tissue |
US20090303317A1 (en) * | 2006-02-07 | 2009-12-10 | Novadaq Technologies Inc. | Near infrared imaging |
WO2007103235A2 (en) * | 2006-03-03 | 2007-09-13 | Prescient Medical, Inc. | Optical imaging balloon catheters |
US20070208257A1 (en) * | 2006-03-03 | 2007-09-06 | Furnish Simon M | Lateral Viewing Optical Catheters |
DE602007009051D1 (de) * | 2006-03-03 | 2010-10-21 | Prescient Medical Inc | Endoluminale prothese zur behandlung von empfindlicher plaque |
US20070225795A1 (en) * | 2006-03-24 | 2007-09-27 | Juan Granada | Composite vascular prosthesis |
US20080140182A1 (en) * | 2006-04-28 | 2008-06-12 | Patricia Scheller | Composite endoluminal prostheses for treating vulnerable plaque |
US8187189B2 (en) * | 2006-04-28 | 2012-05-29 | The Invention Science Fund I, Llc | Imaging via blood vessels |
US20080002927A1 (en) * | 2006-06-12 | 2008-01-03 | Prescient Medical, Inc. | Miniature fiber optic spectroscopy probes |
EP2077748A2 (de) * | 2006-08-22 | 2009-07-15 | Bayer Healthcare, LLC | Verfahren zur korrektur eines spektralbildes für optische aberrationen mit software |
US7603151B2 (en) * | 2006-08-22 | 2009-10-13 | Bayer Healthcare Llc | Non-invasive methods of using spectral information in determining analyte concentrations |
WO2008064130A2 (en) * | 2006-11-17 | 2008-05-29 | Bloom Matthew B | Mir spectroscopy of tissue |
US7990532B2 (en) | 2007-01-16 | 2011-08-02 | Chemimage Corporation | Method and apparatus for multimodal detection |
US9566030B2 (en) | 2007-02-01 | 2017-02-14 | Ls Biopath, Inc. | Optical system for detection and characterization of abnormal tissue and cells |
EP2160217A1 (de) * | 2007-06-08 | 2010-03-10 | Prescient Medical, Inc. | Optische katheterkonfigurationen mit einer kombination aus raman-spektroskopie und niederkohärenz-reflektometrie auf faseroptik-basis |
WO2009018475A1 (en) | 2007-08-01 | 2009-02-05 | Prescient Medical, Inc. | Expandable prostheses for treating atherosclerotic lesions including vulnerable plaques |
US20090062662A1 (en) | 2007-08-27 | 2009-03-05 | Remicalm, Llc | Optical spectroscopic device for the identification of cervical cancer |
US20090099460A1 (en) * | 2007-10-16 | 2009-04-16 | Remicalm Llc | Method and device for the optical spectroscopic identification of cervical cancer |
US9717896B2 (en) | 2007-12-18 | 2017-08-01 | Gearbox, Llc | Treatment indications informed by a priori implant information |
US8280484B2 (en) | 2007-12-18 | 2012-10-02 | The Invention Science Fund I, Llc | System, devices, and methods for detecting occlusions in a biological subject |
US20090287120A1 (en) | 2007-12-18 | 2009-11-19 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Circulatory monitoring systems and methods |
US8636670B2 (en) | 2008-05-13 | 2014-01-28 | The Invention Science Fund I, Llc | Circulatory monitoring systems and methods |
US9672471B2 (en) | 2007-12-18 | 2017-06-06 | Gearbox Llc | Systems, devices, and methods for detecting occlusions in a biological subject including spectral learning |
US8983580B2 (en) | 2008-01-18 | 2015-03-17 | The Board Of Trustees Of The University Of Illinois | Low-coherence interferometry and optical coherence tomography for image-guided surgical treatment of solid tumors |
US7751057B2 (en) | 2008-01-18 | 2010-07-06 | The Board Of Trustees Of The University Of Illinois | Magnetomotive optical coherence tomography |
US8115934B2 (en) | 2008-01-18 | 2012-02-14 | The Board Of Trustees Of The University Of Illinois | Device and method for imaging the ear using optical coherence tomography |
US9560994B2 (en) | 2008-03-26 | 2017-02-07 | Covidien Lp | Pulse oximeter with adaptive power conservation |
TR201901658T4 (tr) | 2008-05-20 | 2019-02-21 | Univ Health Network | Floresan bazli görüntüleme ve i̇zleme i̇çi̇n ci̇haz ve metot |
DE102008034008B4 (de) | 2008-07-21 | 2010-07-01 | Carl Zeiss Surgical Gmbh | Filtersatz zur Beobachtung von Fluoreszenzstrahlung in biologischem Gewebe |
US8416405B2 (en) | 2008-08-08 | 2013-04-09 | Chemimage Corporation | Raman chemical imaging of implantable drug delivery devices |
US20100081926A1 (en) * | 2008-09-29 | 2010-04-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Histological facilitation systems and methods |
US20100081916A1 (en) * | 2008-09-29 | 2010-04-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware. | Histological facilitation systems and methods |
US20100081928A1 (en) * | 2008-09-29 | 2010-04-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Histological Facilitation systems and methods |
US20100081924A1 (en) * | 2008-09-29 | 2010-04-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Histological facilitation systems and methods |
US20100081915A1 (en) * | 2008-09-29 | 2010-04-01 | Searete Llc, Alimited Liability Corporation Of The State Of Delaware | Histological facilitation systems and methods |
US20100081927A1 (en) * | 2008-09-29 | 2010-04-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Histological facilitation systems and methods |
US9186128B2 (en) * | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US20100113906A1 (en) * | 2008-11-06 | 2010-05-06 | Prescient Medical, Inc. | Hybrid basket catheters |
WO2010103661A1 (ja) * | 2009-03-13 | 2010-09-16 | 京都府公立大学法人 | ラマン散乱を用いた生体組織イメージング |
EP2417435A4 (de) | 2009-04-07 | 2014-09-10 | Rare Light Inc | Perikritische reflexionsspektroskope, systeme und verfahren |
US8702321B2 (en) | 2009-12-03 | 2014-04-22 | Eric T. Marple | Filtered fiber optic probe |
US8971998B2 (en) | 2009-12-31 | 2015-03-03 | Integral Electromagnetronic Technologies Llc | Systems and methods for multispectral scanning and detection for medical diagnosis |
US8812084B1 (en) * | 2009-12-31 | 2014-08-19 | Albert Francis Messano, JR. | Systems and methods for multispectral scanning and detection for medical diagnosis |
US20130137134A1 (en) * | 2010-03-29 | 2013-05-30 | Ben Gurion University Of The Negev Research And Development Authority | Method and system for detecting and monitoring hematological cancer |
WO2011151825A2 (en) * | 2010-06-01 | 2011-12-08 | Todos Medical Ltd. | Diagnosis of cancer |
JP5672058B2 (ja) * | 2010-07-02 | 2015-02-18 | ソニー株式会社 | スペクトルデータ解析装置、生体内物質検出システム及び生体内物質検出方法 |
US8432542B2 (en) | 2011-01-10 | 2013-04-30 | Eric T. Marple | Fiber optic probes utilizing GRIN lenses for spatially precise optical spectroscopy |
JP5466182B2 (ja) * | 2011-01-11 | 2014-04-09 | 富士フイルム株式会社 | 内視鏡システムおよび内視鏡システムの作動方法 |
US8970838B2 (en) | 2011-04-29 | 2015-03-03 | Avolonte Health LLC | Method and apparatus for evaluating a sample through variable angle Raman spectroscopy |
EP2707710B1 (de) | 2011-05-11 | 2022-08-17 | Todos Medical Ltd. | Krebsdiagnose auf der grundlage infrarot-spektroskopischer analyse getrockneter blutplasma-proben |
JP6398093B2 (ja) * | 2012-04-13 | 2018-10-03 | ベイカー ハート アンド ダイアベーツ インスティテュート | アテローム斑の検出 |
US10499984B2 (en) | 2012-07-18 | 2019-12-10 | Bernard Boon Chye Lim | Apparatus and method for assessing tissue treatment |
US10881459B2 (en) | 2012-07-18 | 2021-01-05 | Bernard Boon Chye Lim | Apparatus and method for assessing tissue treatment |
US9526426B1 (en) | 2012-07-18 | 2016-12-27 | Bernard Boon Chye Lim | Apparatus and method for assessing tissue composition |
US9804145B2 (en) | 2013-05-28 | 2017-10-31 | Todos Medical Ltd. | Infrared analysis of benign tumors |
US9645086B2 (en) * | 2013-08-30 | 2017-05-09 | Kabushiki Kaisha Toshiba | Componential analysis method, componential analysis apparatus and non-transitory computer-readable recording medium |
US10188330B1 (en) | 2014-02-05 | 2019-01-29 | Covidien Lp | Methods and systems for determining a light drive parameter limit in a physiological monitor |
US10697953B2 (en) | 2014-06-18 | 2020-06-30 | Texas Tech University System | Portable apparatus for liquid chemical characterization |
US11187692B2 (en) | 2014-06-18 | 2021-11-30 | Texas Tech University System | Enhanced chemical characterization of solid matrices using x-ray fluorescence and optical color reflectance |
CN106714670A (zh) | 2014-07-24 | 2017-05-24 | 大学健康网络 | 用于诊断目的的数据的收集和分析 |
WO2016201572A1 (en) * | 2015-06-16 | 2016-12-22 | Dalhousie University | Methods of detection of steatosis |
CN105520719A (zh) * | 2016-01-25 | 2016-04-27 | 上海电力学院 | 一种基于红外光谱的早期癌细胞检测系统 |
US10293122B2 (en) | 2016-03-17 | 2019-05-21 | Novadaq Technologies ULC | Endoluminal introducer with contamination avoidance |
KR102574088B1 (ko) * | 2018-08-10 | 2023-09-04 | 삼성전자주식회사 | 분석 물질의 농도 추정 장치 및 방법과, 농도 추정 모델 생성 장치 및 방법 |
US10588514B1 (en) * | 2019-04-29 | 2020-03-17 | Hua Shang | Vivo photon analysis system and method |
JP7524305B2 (ja) | 2019-08-12 | 2024-07-29 | バード・アクセス・システムズ,インコーポレーテッド | 医療機器用の形状センシングシステム |
US11965823B2 (en) | 2019-08-28 | 2024-04-23 | Foss Analytical A/S | Method of correcting for an amplitude change in a spectrometer |
KR20210057506A (ko) * | 2019-11-12 | 2021-05-21 | 삼성전자주식회사 | 피부 장벽 기능 추정 장치 및 방법 |
US11525670B2 (en) | 2019-11-25 | 2022-12-13 | Bard Access Systems, Inc. | Shape-sensing systems with filters and methods thereof |
CN214804697U (zh) | 2019-11-25 | 2021-11-23 | 巴德阿克塞斯系统股份有限公司 | 光学尖端追踪系统 |
US11474310B2 (en) | 2020-02-28 | 2022-10-18 | Bard Access Systems, Inc. | Optical connection systems and methods thereof |
EP4127798A1 (de) | 2020-03-30 | 2023-02-08 | Bard Access Systems, Inc. | Optische und elektrische diagnosesysteme und verfahren dafür |
EP3910323A1 (de) * | 2020-05-12 | 2021-11-17 | CIC nanoGUNE - Asociación Centro de Investigación Cooperativa en Nanociencias | Kombiniertes spektroskopiesystem mit raman und atr-ftir |
US11622816B2 (en) | 2020-06-26 | 2023-04-11 | Bard Access Systems, Inc. | Malposition detection system |
CN113926050A (zh) | 2020-06-29 | 2022-01-14 | 巴德阿克塞斯系统股份有限公司 | 用于光纤的自动尺寸参考系 |
CN216317552U (zh) | 2020-07-10 | 2022-04-19 | 巴德阿克塞斯系统股份有限公司 | 用于检测医疗装置的光纤技术的损坏和潜在损坏的医疗装置系统 |
WO2022031613A1 (en) | 2020-08-03 | 2022-02-10 | Bard Access Systems, Inc. | Bragg grated fiber optic fluctuation sensing and monitoring system |
WO2022067096A1 (en) | 2020-09-25 | 2022-03-31 | Bard Access Systems, Inc. | Fiber optics oximetry system for detection and confirmation |
EP4229456A1 (de) | 2020-10-13 | 2023-08-23 | Bard Access Systems, Inc. | Desinfektionsabdeckungen für funktionelle verbinder medizinischer vorrichtungen und verfahren dafür |
CN112353378A (zh) * | 2020-11-04 | 2021-02-12 | 上海交通大学医学院附属瑞金医院 | 一种基于平行结构探测体的微循环探测装置及系统 |
US12089815B2 (en) | 2022-03-17 | 2024-09-17 | Bard Access Systems, Inc. | Fiber optic medical systems and devices with atraumatic tip |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3327117A (en) | 1963-08-12 | 1967-06-20 | Ibm | Cancer cell detector using two wavelengths for comparison |
US3327119A (en) | 1964-03-26 | 1967-06-20 | Ibm | Method and apparatus for detecting cancer cells |
US3461856A (en) | 1965-10-23 | 1969-08-19 | American Optical Corp | Oximeters |
US3647299A (en) | 1970-04-20 | 1972-03-07 | American Optical Corp | Oximeter |
JPS6043134B2 (ja) | 1977-08-25 | 1985-09-26 | 信紘 佐藤 | 生体の臓器,組識の反射特性測定装置 |
US4290433A (en) | 1979-08-20 | 1981-09-22 | Alfano Robert R | Method and apparatus for detecting the presence of caries in teeth using visible luminescence |
DE2934190A1 (de) * | 1979-08-23 | 1981-03-19 | Müller, Gerhard, Prof. Dr.-Ing., 7080 Aalen | Verfahren und vorrichtung zur molekuelspektroskopie, insbesondere zur bestimmung von stoffwechselprodukten |
US4515165A (en) | 1980-02-04 | 1985-05-07 | Energy Conversion Devices, Inc. | Apparatus and method for detecting tumors |
SU922050A1 (ru) | 1980-06-26 | 1982-04-23 | Алтайский Филиал Всесоюзного Проектно-Конструкторского Технологического Института Атомного Машиностроения И Котлостроения | Стрела грузоподъемного крана |
FR2521727A2 (fr) | 1981-03-25 | 1983-08-19 | Cilas | Dispositif pour mesurer l'etat d'oxydo-reduction d'un organe vivant in situ |
US4479499A (en) | 1982-01-29 | 1984-10-30 | Alfano Robert R | Method and apparatus for detecting the presence of caries in teeth using visible light |
US4445892A (en) * | 1982-05-06 | 1984-05-01 | Laserscope, Inc. | Dual balloon catheter device |
JPS5940830A (ja) | 1982-08-31 | 1984-03-06 | 浜松ホトニクス株式会社 | レ−ザ光パルスを用いた癌の診断装置 |
US4541438A (en) | 1983-06-02 | 1985-09-17 | The Johns Hopkins University | Localization of cancerous tissue by monitoring infrared fluorescence emitted by intravenously injected porphyrin tumor-specific markers excited by long wavelength light |
US4768516A (en) | 1983-10-14 | 1988-09-06 | Somanetics Corporation | Method and apparatus for in vivo evaluation of tissue composition |
US4620284A (en) * | 1983-12-29 | 1986-10-28 | Uop Inc. | Qualitative and quantitative analysis using Raman scattering |
US4737628A (en) | 1984-02-07 | 1988-04-12 | International Technical Associates | Method and system for controlled and selective removal of material |
US4641650A (en) | 1985-03-11 | 1987-02-10 | Mcm Laboratories, Inc. | Probe-and-fire lasers |
US4718417A (en) | 1985-03-22 | 1988-01-12 | Massachusetts Institute Of Technology | Visible fluorescence spectral diagnostic for laser angiosurgery |
US4758081A (en) | 1985-07-18 | 1988-07-19 | Bausch & Lomb Incorporated | Control of laser photocoagulation using Raman radiation |
US4930516B1 (en) | 1985-11-13 | 1998-08-04 | Laser Diagnostic Instr Inc | Method for detecting cancerous tissue using visible native luminescence |
US4810875A (en) * | 1987-02-02 | 1989-03-07 | Wyatt Technology Corporation | Method and apparatus for examining the interior of semi-opaque objects |
DE3813227A1 (de) * | 1987-05-25 | 1989-01-12 | Messerschmitt Boelkow Blohm | Einrichtung zur zirkumferenziellen bestrahlung von objekten |
WO1989002718A1 (en) | 1987-09-24 | 1989-04-06 | Massachusetts Institute Of Technology | Catheter system for imaging |
US4894547A (en) | 1987-09-28 | 1990-01-16 | Yale University | Optical method and apparatus for detecting and measuring aging, photoaging, dermal disease and pigmentation in skin |
US4981138A (en) | 1988-06-30 | 1991-01-01 | Yale University | Endoscopic fiberoptic fluorescence spectrometer |
WO1990006718A1 (en) * | 1988-12-21 | 1990-06-28 | Massachusetts Institute Of Technology | A method for laser induced fluorescence of tissue |
SE8900612D0 (sv) * | 1989-02-22 | 1989-02-22 | Jonas Johansson | Vaevnadskarakterisering utnyttjande ett blodfritt fluorescenskriterium |
US5042980A (en) * | 1989-05-26 | 1991-08-27 | C. R. Bard, Inc. | Optical fiber diffusion tip for uniform illumination |
US4975581A (en) * | 1989-06-21 | 1990-12-04 | University Of New Mexico | Method of and apparatus for determining the similarity of a biological analyte from a model constructed from known biological fluids |
US5261410A (en) * | 1991-02-07 | 1993-11-16 | Alfano Robert R | Method for determining if a tissue is a malignant tumor tissue, a benign tumor tissue, or a normal or benign tissue using Raman spectroscopy |
JPH06505183A (ja) * | 1991-02-26 | 1994-06-16 | マサチユセツツ・インスチチユート・オブ・テクノロジー | 組織を診断するための分子分光計のシステムおよび方法 |
US5293872A (en) * | 1991-04-03 | 1994-03-15 | Alfano Robert R | Method for distinguishing between calcified atherosclerotic tissue and fibrous atherosclerotic tissue or normal cardiovascular tissue using Raman spectroscopy |
-
1992
- 1992-01-17 JP JP4506208A patent/JPH06505183A/ja active Pending
- 1992-01-17 CA CA002104960A patent/CA2104960C/en not_active Expired - Fee Related
- 1992-01-17 WO PCT/US1992/000420 patent/WO1992015008A1/en active IP Right Grant
- 1992-01-17 US US08/107,854 patent/US6690966B1/en not_active Expired - Lifetime
- 1992-01-17 AT AT92906273T patent/ATE198375T1/de active
- 1992-01-17 EP EP92906273A patent/EP0573535B1/de not_active Expired - Lifetime
- 1992-01-17 DE DE69231614T patent/DE69231614T2/de not_active Expired - Lifetime
-
1994
- 1994-08-11 US US08/288,990 patent/US6697665B1/en not_active Expired - Lifetime
-
2004
- 2004-01-27 US US10/765,754 patent/US20040186383A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO9215008A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3607875A1 (de) * | 2018-08-10 | 2020-02-12 | Samsung Electronics Co., Ltd. | Bestimmung einer analytkonzentration mittels raman-spektroskopie |
Also Published As
Publication number | Publication date |
---|---|
US20040186383A1 (en) | 2004-09-23 |
EP0573535B1 (de) | 2000-12-27 |
DE69231614T2 (de) | 2001-05-03 |
CA2104960A1 (en) | 1992-08-27 |
US6697665B1 (en) | 2004-02-24 |
US6690966B1 (en) | 2004-02-10 |
JPH06505183A (ja) | 1994-06-16 |
ATE198375T1 (de) | 2001-01-15 |
DE69231614D1 (de) | 2001-02-01 |
WO1992015008A1 (en) | 1992-09-03 |
CA2104960C (en) | 2005-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6690966B1 (en) | Methods of molecular spectroscopy to provide for the diagnosis of tissue | |
US20020156380A1 (en) | Raman endoscope | |
US6208887B1 (en) | Catheter-delivered low resolution Raman scattering analyzing system for detecting lesions | |
US6091984A (en) | Measuring tissue morphology | |
US20170202462A1 (en) | Systems and methods for spectroscopy of biological tissue | |
JP4870356B2 (ja) | 組織を測定するための高波数ラマン分光法の使用 | |
US5042494A (en) | Method and apparatus for detecting cancerous tissue using luminescence excitation spectra | |
JP4474050B2 (ja) | マルチモード光学組織診断システム | |
US20090326385A1 (en) | Obtaining optical tissue properties | |
Mourant et al. | Elastic scattering spectroscopy as a diagnostic tool for differentiating pathologies in the gastrointestinal tract: preliminary testing | |
US7508524B2 (en) | Combined raman spectroscopy-optical coherence tomography (RS-OCT) system and applications of the same | |
EP2327978A2 (de) | Vorrichtung und Verfahren zur Spektroskopie von biologischem Gewebe | |
CA2658811C (en) | Multi modal spectroscopy | |
US9788728B2 (en) | Endoscopic polarized multispectral light scattering scanning method | |
US20050203419A1 (en) | Side-firing probe for performing optical spectroscopy during core needle biopsy | |
EP1495309A1 (de) | Vorrichtungen und verfahren für die spektroskopie von biologischem gewebe | |
US20100317974A1 (en) | Detection of vulnerable plaques by raman spectroscopy | |
Tunnell et al. | Diagnostic tissue spectroscopy and its applications to gastrointestinal endoscopy | |
CA2497575A1 (en) | Systems and methods of molecular spectroscopy to provide for the diagnosis of tissue | |
Manoharan et al. | Raman spectroscopy for cancer detection: instrument development and tissue diagnosis | |
Fitzmaurice et al. | Raman spectroscopy: development of clinical applications for breast cancer diagnosis | |
Van de Poll et al. | Prospects of laser spectroscopy to detect vulnerable plaque | |
RU2152162C1 (ru) | Способ повышения точности обнаружения злокачественных новообразований и определения границ их локализации | |
Moreno et al. | Near‐Infrared Spectroscopy | |
Chau | Development of an intracoronary Raman spectroscopy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19930924 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
17Q | First examination report despatched |
Effective date: 19940118 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 20001227 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20001227 Ref country code: LI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20001227 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRE;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.SCRIBED TIME-LIMIT Effective date: 20001227 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20001227 Ref country code: ES Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 20001227 Ref country code: CH Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20001227 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20001227 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20001227 |
|
REF | Corresponds to: |
Ref document number: 198375 Country of ref document: AT Date of ref document: 20010115 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010117 |
|
REF | Corresponds to: |
Ref document number: 69231614 Country of ref document: DE Date of ref document: 20010201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010227 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20010327 |
|
ET | Fr: translation filed | ||
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20050112 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20050117 Year of fee payment: 14 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060117 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060131 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20060117 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20060929 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20100127 Year of fee payment: 19 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69231614 Country of ref document: DE Effective date: 20110802 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110802 |